Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 5/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2654491 | 0.85 | NAMPT (0.51) | EHMT2TP53CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL9251618 | 0.84 | JAK2 (0.51) | MAPTKDM4EALDH1A1HPGDEHMT2 | |
| SCHEMBL2653215 | 0.84 | PTGER4 (0.46) | ENPP2MAPTKDM4EALDH1A1HPGD | |
| Bromide SCHEMBL9248810 | 0.83 | JAK2 (0.50) | MAPTKDM4EALDH1A1HPGDEHMT2 | |
| SCHEMBL2659921 | 0.83 | EHMT2 (0.51) | MAPTEHMT2TP53PTGER4PIN1 | |
| SCHEMBL2652219 | 0.81 | GCGR (0.50) | ENPP2CYP1A2CYP2C9CYP3A4CYP2B6 | |
| SCHEMBL9253344 | 0.81 | JAK2 (0.52) | MAPTEHMT2TP53PTGER4PIN1 | |
| SCHEMBL2653126 | 0.81 | HDAC1 (0.61) | MAPTKDM4EALDH1A1HPGDEHMT2 | |
| SCHEMBL9245485 | 0.81 | PTGER4 (0.48) | ENPP2MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL9247747 | 0.81 | PTGER4 (0.49) | MAPTKDM4EALDH1A1HPGDEHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212119-A1 | Novel glucagon receptor antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-11-13 | — | — | US | disclosed |
| WO-2003053938-A1 | BENZIMIDAZOLS AND INDOLS AS GLUCAGON RECEPTOR ANTAGONISTS/INVERSE AGONISTEN | NOVO NORDISK A/S (DK) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212119-A1 | Novel glucagon receptor antagonists/inverse agonists | GLP1R, GCGR, GIPR | ENPP2 276/4885MAPT 4512/4885KDM4E 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.